What is IBANDRONATE SODIUM used for?

IBANDRONATE SODIUM (brand name IBANDRONATE SODIUM) is a Bisphosphonate indicated for See full prescribing information.

What are the most common side effects of IBANDRONATE SODIUM?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for IBANDRONATE SODIUM. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is IBANDRONATE SODIUM the same as IBANDRONATE SODIUM?

IBANDRONATE SODIUM is a brand name for IBANDRONATE SODIUM. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

IBANDRONATE SODIUM

Q: How does IBANDRONATE SODIUM work?

IBANDRONATE SODIUM works through the following mechanism: 12.1 Mechanism of Action The action of ibandronate on bone tissue is based on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Ibandronate inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass..

Bisphosphonate

Brand names: IBANDRONATE SODIUM, Boniva

Oral

Mechanism of Action

12.1 Mechanism of Action The action of ibandronate on bone tissue is based on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Ibandronate inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

Indications

See full prescribing information

Contraindications

• 5.1 ) Inability to stand or sit upright for at least 60 minutes ( 4
• 5.1 ) Hypocalcemia ( 4 ) Hypersensitivity to ibandronate sodium tablets ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS Upper gastrointestinal Adverse Reactions can occur
Risk/benefit of continuing bisphosphonate therapy should be re-evaluated in these patients and interruption of bisphosphonate therapy should be considered
The risk of severe esophageal adverse experiences appears to be greater in patients who lie down after taking oral bisphosphonates and/or who fail to swallow it with the recommended full glass (6 to 8 oz) of water, and/or who continue to take oral bisphosphonates after developing symptoms suggestive of esophageal irritation
There have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications, although no increased risk was observed in controlled clinical trials

Known Side Effects

13 documented side effects by frequency

Joint Pain

1-10%

Diarrhea

1-10%

Nausea

1-10%

Headache

1-10%

Fatigue

1-10%

Falls

1-10%

Dizziness

1-10%

Weakness

1-10%

Muscle Pain

1-10%

Drug Not Working

1-10%

Limb Pain

1-10%

Vomiting

1-10%

Back Pain

1-10%

Community Discussions

No community discussions found for IBANDRONATE SODIUM yet.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → IBANDRONATE SODIUM openFDA label JSON → IBANDRONATE SODIUM FAERS adverse-event reports → IBANDRONATE SODIUM ClinicalTrials.gov → completed Phase 2+ trials of IBANDRONATE SODIUM

Compare With

3 available comparisons

Formulations

Dosage Forms

Tablet

Route

Oral